Form 4: Cytokinetics CEO Robert Blum Reports Stock Sale
SEC Form 4 Filing
Cytokinetics CEO Robert Blum sold 5,000 shares of common stock at a price of $40.96 on April 29, 2025, according to a Form 4 filing.
Summary
- On April 29, 2025, Robert I Blum, the President & CEO of Cytokinetics Inc, reported a transaction involving the company's common stock.
- Blum sold 5,000 shares of common stock at a price of $40.96 per share.
- Following the transaction, Blum directly owns 417,629 shares of Cytokinetics Inc.
- Blum also indirectly owns 2,083 shares through The Bridget Blum 2003 Irrevocable Trust and 2,083 shares through The Brittany Blum 2003 Irrevocable Trust.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a stock sale by the CEO. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transaction.
Industry Context
Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. Investors often monitor these filings to gain insights into management's perspective on the company's stock.
Stakeholder Impact
- Shareholders may interpret the CEO's stock sale in various ways, potentially affecting investor confidence.
Key Dates
| Date | Description |
|---|---|
| 04/29/2025 | Date of stock sale transaction and filing date. |
Keywords
Form 4, insider trading, stock sale, Robert Blum, Cytokinetics, CYTK
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.